Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

488 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
Ravandi F, Subklewe M, Walter RB, Vachhani P, Ossenkoppele G, Buecklein V, Döhner H, Jongen-Lavrencic M, Baldus CD, Fransecky L, Pardee TS, Kantarjian H, Yen PK, Mukundan L, Panwar B, Yago MR, Agarwal S, Khaldoyanidi SK, Stein A. Ravandi F, et al. Among authors: ossenkoppele g. Leuk Lymphoma. 2024 Sep;65(9):1281-1291. doi: 10.1080/10428194.2024.2346755. Epub 2024 May 7. Leuk Lymphoma. 2024. PMID: 38712673 Clinical Trial.
Cytarabine dose for acute myeloid leukemia.
Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Löwenberg B, et al. N Engl J Med. 2011 Mar 17;364(11):1027-36. doi: 10.1056/NEJMoa1010222. N Engl J Med. 2011. PMID: 21410371 Free article. Clinical Trial.
Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance.
Sobas MA, Turki AT, Ramiro AV, Hernández-Sánchez A, Elicegui JM, González T, Melchor RA, Abáigar M, Tur L, Dall'Olio D, Sträng E, Tettero JM, Castellani G, Benner A, Döhner K, Thiede C, Metzeler KH, Haferlach T, Damm F, Ayala R, Martínez-López J, Mills KI, Sierra J, Lehmann S, Porta MGD, Mayer J, Reinhardt D, Medina RV, Schulze-Rath R, Barbus M, Hernández-Rivas JM, Huntly BJP, Ossenkoppele G, Döhner H, Bullinger L. Sobas MA, et al. Among authors: ossenkoppele g. Haematologica. 2024 Nov 7. doi: 10.3324/haematol.2024.285805. Online ahead of print. Haematologica. 2024. PMID: 39506894 Free article.
Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project.
Voso MT, Guarnera L, Lehmann S, Döhner K, Döhner H, Platzbecker U, Russell NH, Dillon RJ, Thomas I, Ossenkoppele GJ, Haferlach T, Vignetti M, La Sala E, Piciocchi A, Fazi P, Villaverde Ramiro Á, Tur Giménez L, Gurnari C, Bullinger L, Hernandez JM. Voso MT, et al. Among authors: ossenkoppele gj. Blood. 2024 Nov 6:blood.2024026186. doi: 10.1182/blood.2024026186. Online ahead of print. Blood. 2024. PMID: 39504485
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.
Huls G, Chitu DA, Tick L, Boersma R, Breems D, Herbers A, Klein SK, de Jonge S, Westerweel PE, Cruijsen M, Hoogendoorn M, Cuijpers M, Deeren D, Bailly B, Visser O, van Rhenen A, Posthuma EFM, Valk PJM, Cloos J, Ammatuna E, Refos JM, Fakkert R, Löwenberg B, Ossenkoppele GJ. Huls G, et al. Among authors: ossenkoppele gj. Ann Hematol. 2024 Oct 5. doi: 10.1007/s00277-024-06033-y. Online ahead of print. Ann Hematol. 2024. PMID: 39367118
Risk Stratification in Older Intensively Treated Patients With AML.
Versluis J, Metzner M, Wang A, Gradowska P, Thomas A, Jakobsen NA, Kennedy A, Moore R, Boertjes E, Vonk CM, Kavelaars FG, Rijken M, Gilkes A, Schwab C, Beverloo HB, Manz M, Visser O, Van Elssen CHMJ, de Weerdt O, Tick LW, Biemond BJ, Vekemans MC, Freeman SD, Harrison CJ, Cook JA, Dennis M, Knapper S, Thomas I, Craddock C, Ossenkoppele GJ, Löwenberg B, Russell N, Valk PJM, Vyas P. Versluis J, et al. Among authors: ossenkoppele gj. J Clin Oncol. 2024 Dec;42(34):4084-4094. doi: 10.1200/JCO.23.02631. Epub 2024 Sep 4. J Clin Oncol. 2024. PMID: 39231389 Free PMC article.
The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells.
Reuvekamp T, Janssen LLG, Ngai LL, Carbaat-Ham J, den Hartog D, Scholten WJ, Kelder A, Hanekamp D, Wensink E, van Gils N, Gradowska P, Löwenberg B, Ossenkoppele GJ, van de Loosdrecht AA, Westers TM, Smit L, Bachas C, Cloos J. Reuvekamp T, et al. Among authors: ossenkoppele gj. Cytometry B Clin Cytom. 2024 Aug 23. doi: 10.1002/cyto.b.22201. Online ahead of print. Cytometry B Clin Cytom. 2024. PMID: 39177948
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML).
Rodríguez-Arbolí E, Othus M, Freeman SD, Buccisano F, Ngai LL, Thomas I, Palmieri R, Cloos J, Johnson S, Meddi E, Russell NH, Venditti A, Gradowska P, Ossenkoppele GJ, Löwenberg B, Walter RB. Rodríguez-Arbolí E, et al. Among authors: ossenkoppele gj. Leukemia. 2024 Oct;38(10):2266-2269. doi: 10.1038/s41375-024-02378-5. Epub 2024 Aug 21. Leukemia. 2024. PMID: 39169114 No abstract available.
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.
Döhner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Wei AH, Löwenberg B. Döhner H, et al. Among authors: ossenkoppele g. Blood. 2024 Nov 21;144(21):2169-2173. doi: 10.1182/blood.2024025409. Blood. 2024. PMID: 39133932
488 results